Statement from NIH and BARDA on the FDA Emergency Use Authorization of the Janssen COVID-19 Vaccine, February 27, 2021 – National Institutes of Health

News ReleaseSaturday, February 27, 2021
Today, the U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) to the Janssen Pharmaceuticals Companies of Johnson & & Johnson for its single-shot COVID-19 vaccine, called Ad.26. COV2S or JNJ-78436725. The Janssen vaccine is a recombinant vector vaccine that uses a human adenovirus to express the spike protein discovered on the surface area of the SARS-CoV-2 infection that triggers COVID-19. Adenoviruses are a group of viruses that trigger infections in the gastrointestinal and breathing systems; the adenovirus vector utilized in the Janssen COVID-19 vaccine has actually been modified so it no longer can reproduce in human beings and cause illness. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, supported late-stage scientific screening of the Janssen vaccine. It is the 3rd COVID-19 vaccine in the United States to be approved an EUA by FDA. NIH Director Francis S. Collins, M.D. Ph.D., NIAID Director Anthony S. Fauci, M.D., and BARDA Director Gary Disbrow, Ph.D., released the following declarations:

” The Janssen COVID-19 vaccine is a very welcome really to the arsenal of COVID-19 vaccines and other prevention strategiesAvoidance When tested among 45,000 volunteers, the single-injection vaccine proved 77 percent reliable in avoiding severe/critical COVID-19 taking place at least 14 days after vaccination and 85 percent efficient in preventing severe/critical COVID-19 happening at least 28 days after vaccination. The vaccine was roughly 67 percent effective in avoiding moderate-to-severe/critical COVID-19 disease occurring at least 14 days after vaccination and 66 percent reliable in avoiding moderate-to-severe/critical COVID-19 disease occurring at least 28 days after vaccination.– NIAID Director Anthony S. Fauci, M.D.

— NIH Director Francis S. Collins, M.D., Ph.D.

Anthony S. Fauci, M.D., is Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health in Bethesda, Maryland.

NIAID supports and conducts research study– at NIH, throughout the United States, and worldwide– to study the causes of immune-mediated and infectious illness, and to establish better methods of preventing, identifying and dealing with these health problems. Press release, reality sheets and other NIAID-related materials are available on the NIAID website.About the National Institutes of Health (NIH):.
NIH, the countrys medical research study company, includes 27 Institutes and Centers and belongs of the U.S. Department of Health and Human Services. NIH is the primary federal company conducting and supporting standard, scientific, and translational medical research, and is examining the causes, treatments, and treatments for both rare and typical illness. For additional information about NIH and its programs, check out www.nih.gov.

NIH … Turning Discovery Into Health ® ###.

” The Janssen COVID-19 vaccine is a very welcome addition to the arsenal of COVID-19 vaccines and other prevention strategies. When checked among 45,000 volunteers, the single-injection vaccine showed 77 percent efficient in avoiding severe/critical COVID-19 happening at least 14 days after vaccination and 85 percent efficient in avoiding severe/critical COVID-19 occurring at least 28 days after vaccination. The vaccine was around 67 percent reliable in avoiding moderate-to-severe/critical COVID-19 disease occurring at least 14 days after vaccination and 66 percent efficient in avoiding moderate-to-severe/critical COVID-19 disease taking place at least 28 days after vaccination.

Gary Disbrow, Ph.D., is Director of the Biomedical Advanced Research and Development Authority (BARDA), in the HHS Office of the Assistant Secretary for Preparedness and Response.

The Janssen vaccine is a recombinant vector vaccine that uses a human adenovirus to express the spike protein found on the surface of the SARS-CoV-2 virus that triggers COVID-19.– NIH Director Francis S. Collins, M.D., Ph.D.

” The FDAs emergency use emergency situation of the Janssen COVID-19 vaccine is exciting news on many frontsLots of

Leave a Reply

Your email address will not be published. Required fields are marked *